Dec 11, 2022 / 02:00PM GMT
Operator
Welcome to Adicet's specially scheduled Conference Call. This call is being recorded. At the end of the company's prepared remarks, we'll open the call for questions, and we'll provide specific instructions at that point.
I would now like to turn the call over to Anne Bowdidge. Please go ahead.
Anne Bowdidge -
Good morning. Thank you for joining us. On the call today from Adicet are Chen Schor, President and CEO; Dr. Francesco Galimi, Chief Medical Officer; Nick Harvey, Chief Financial Officer; and Dr. Blake Aftab, Chief Scientific Officer. In addition, we're pleased to have Dr. Sattva Neelapu, Professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center joining us today.
Before we begin, I'd like to remind you that various remarks that we make on this call contain forward-looking statements that are made under the safe harbor provisions of the securities laws, including, but not limited to, expressed or implied statements regarding the potential safety, durability, tolerability and efficacy of ADI-001, future
Adicet Bio Inc To Discuss Recent Data-Cut Date From Phase 1 Study Call Transcript
Dec 11, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers